European Psychiatry - Volume 41 - April 2017

101 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S69–S105 S97
2 University of Bern, Translational Research Center–University
Hospital of Psychiatry and Psychotherapy, Bern, Switzerland
3 University of Rome Tor Vergata, Department of Systems Medicine,
Rome, Italy
4 University of Foggia, Department of Clinical and Experimental
Medicine–Psychiatry Unit, Foggia, Italy
∗ Corresponding author.
Introduction Negative symptoms are a core feature of
schizophrenia but their pathophysiology remains elusive. They
cluster in a motivation-related domain, including apathy, anhe-
donia, asociality and in an expression-related domain, including
alogia and blunted affect.
Aim Our aim was to investigate the different neurobiologi-
cal underpinnings of the two domains using the brain electrical
microstates (MS), which reflect global patterns of functional con-
nectivity with high temporal resolution.
Method We recorded multichannel resting EEGs in 142
schizophrenia patients (SCZ) and in 64 healthy controls (HC),
recruited to the Italian network for research on psychoses study.
Four microstates (MS) classes were computed from resting EEG
data using the K-Mean clustering algorithm. Pearson’s coefficient
was used to investigate correlations of microstates measures
with negative symptom domains, assessed by the Brief Negative
Symptoms Scale (BNSS).
Results SCZ, in comparison to HC, showed increased contribu-
tion and duration of MS-C. Only the avolition domain of BNSS
correlated with the contribution and occurrence of MS-A. Within
the same domain, anticipatory anhedonia, apathy and asociality,
but not consummatory anhedonia, were positively correlated with
contribution and occurrence of microstate A. Asociality was also
negatively correlated with contribution and occurrence of MS-D.
Conclusion Our findings support different neurobiological under-
pinnings of the negative symptom domains, avolition and
expressive deficit. Furthermore, our results lend support to the
hypothesis that only anticipatory anhedonia is linked to the avo-
lition domain of the negative symptoms. Mixed results in the
literature concerning the presence of MS-A and D abnormalities
in schizophrenia might be related to the syndrome heterogeneity.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
O079
Anticipating outcome: Predictors of
first and subsequent relapses in
schizoprenia. A 3-year follow-up
M. Gomez Revuelta ∗ ajardo Galan Juncal Ruiz
O. Porta Olivares andera Rodriguez
G. Pardo De Santayana Jenaro arcia Ayala
L. Sanchez Blanco Fernandez Rodriguez respo Facorro
1 Hospital Universitario de Álava-Sede Santiago- Vitoria-Gasteiz,
Psychiatry, La Penilla, Spain
2 Hospital Universitario Marques de Valdecilla, Psychiatry,
Santander, Spain
3 Hospital Universitario de Álava-Sede Santiago, Psychiatry,
Vitoria-Gasteiz, Spain
∗ Corresponding author.
Introduction Relapse prevention during early stages after psy-
chosis onset is a key factor for long term outcome. While factors
associatedwith first relapse have beenwidely studied, factors asso-
ciated with subsequent relapses are poorly described.
Objectives To determine predictive factors of first and subse-
quent relapses among patients recruited from a cohort of PAFIP
Early Intervention Program.
Material and methods We analyzed socio-demographic and clin-
ical data of a cohort of 393 first episode psychosis (FEP) patients
that were recruited since February 2001 to May 2011. Of these, 341
achieved clinical remission and were, therefore, considered to be
at risk of relapse. They were followed-up for 3 years. A wide range
of potential factors were included as possible predictors of relapse.
Test univariate, analysis logistics of regression, regression of Cox
and analysis of survival of Kaplan-Meier were carried out.
Results Poor adherence to medication was the main predictor
associated to first relapse (ExpB: 2.979; P < 0.001). After the first
relapse, only 56 patients (33.9%) underwent a second relapse, being
the diagnosis (ExpB: 1.975; P = 0.074), the age of onset, (ExpB:
1.078; P = 0.003) and a low level of positive symptomatology (ExpB:
0.863; P = 0.03) the predictors of associated with a second relapse.
Conclusions After a FEP, non-adherence tomedication is themain
predictor of first relapse. Second and subsequent relapses relate
with non-modifiable factors such as age of onset or schizophrenia
diagnosis. This subgroup of patients could have greater predispo-
sition to relapse related with the severity of the disease itself.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
O080
Needs of people with
schizophrenia/psychosis and their
caregivers: A large scale survey
G. Lahera ∗, J. Cid , A. González-Pinto , A. Cabrera ,
I. González , E. Vieta , C. Arango , B. Crespo-Facorro
1 University of Alcalá–CIBERSAM, Psychiatry, Alcalá de Henares,
Madrid, Spain
2 Girona Institute of Health Assistance IdibGi, Mental Health, Girona,
Spain
3 Álava University Hospital–CIBERSAM, Psychiatry, Vitoria, Spain
4 Madrid Association of Friends and Relatives of People with
Schizophrenia, Mental Health, Madrid, Spain
5 Spanish Mental Health Confederation, Mental Health, Madrid, Spain
6 Institut of Neuroscience–Hospital Clinic–University of
Barcelona–IDIBAPS–CIBERSAM, Psychiatry, Barcelona, Spain
7 Gregorio Mara˜nón University Hospital–Complutense University of
Madrid–IiSGM–CIBERSAM, Psychiatry, Madrid, Spain
8 Marqués de Valdecilla University Hospital–University of
Cantabria–CIBERSAM, Psychiatry, Santander, Spain
∗ Corresponding author.
For the first time in Spain, a large scale survey (5205 people) was
carried out to establish the real needs of those directly affected by
the illness. Patients and caregivers responded to a 9-question sur-
vey concerning dimensions: personal, social, medical treatment,
psychotherapy and rehabilitation. For patients, the most impor-
tant need (an average score of 3.5 on a scale of importance from 1
to 4) was to feel their emotional needs covered. The following aver-
age scores were also obtained: feel well physically (3.42), improve
autonomy (3.41), have leisure activities (3.21) and work/study
(3.1). A total of 42% of patients indicated having little or no freedom
over their lives. Thirty-six percent indicated that medical treat-
ment did not start soon enough, 35% that psychotherapy started
too late and 13% saying they had received no psychotherapy at all.
The help from professionals most valued was provide information
about the illness (3.4), dedicatingmore time (3.4) investigating new
treatments (3.3) paying attention to secondary effects (3.3) and
incorporating the patient in decision making (3.3). Most patients
reported a state of health “regular to good” but 10% indicated not
being understood at all in their social environment since onset
of illness and 25% being little understood. The anti-stigma ini-
tiative most valued was to increase investment in schizophrenia
in health planning. Integral health planning should incorporate
patient insights concerning basic needs and treatment preferences.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.